Table 1 Study characteristics of the published studies included in the meta-analysis
From: Relationship of asprosin and diabetes: a meta-analysis
Author | Publication Year | Study Period | Ethnicity | Region | Number (n) | Level of Asprosin | Details | Sample | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Case | Control | Case | Control | Case | Control | ||||||||
Wang Y | 2018 | – | Asian | China | 51 | 52 | 73.25 ± 91.69 ng/mL | 16.22 ± 9.27 ng/mL | M 27, F 24; 53.73 ± 10.06 years; T2DM | M 17, F 35; 54.73 ± 11.90 years | Plasma | ||
Zhang L | 2019 | March to June 2017 | Asian | China | 84 | 86 | 3.52 ± 4.2 ng/mL | 1.77 ± 1.64 ng/mL | M 52, F 32; 49.93 ± 10.99 years; newly diagnosed T2DM | M 49, F 37; 47.60 ± 7.95 years | Serum | ||
Zhang H | 2020 | April to December 2019 | Asian | China | 42 | 30 | 6.23 ± 0.87 ng/mL | 5.08 ± 1.31 ng/mL | M 23, F 19; 55.98 ± 8.59 years; T2DM; duration of DM: 10.0 (6.0–13.0) years | M 14, F 16; 54.30 ± 4.92 years | Serum | ||
Zhong L | 2020 | – | Asian | China | 40 | 40 | 1.35 ± 0.68 ng/mL | 0.5 ± 0.84 ng/mL | All females; 34.18 ± 3.24 years; GDM; gestational age: 270.45 ± 8.81 days | All females; 34.2 ± 3.31 years; gestational age: 273.63 ± 6.51 days | Plasma | ||
Zhang X | 2020 | May to December 2018 | Asian | China | 60 | 60 | 6.2 ± 1.13 ng/mL | 5.22 ± 1.26 ng/mL | M 32, F 28; 56.40 ± 7.49 years; T2DM | M 34, F 26; 54.62 ± 5.97 years | Serum | ||
Naiemian S | 2020 | August to December 2018 | Asian | Iran | 97 | 97 | 4.18 ± 3.26 ng/mL | 3.5 ± 1.37 ng/mL | M 50, F 47; 54 ± 7 years; newly diagnosed T2DM | M 50, F 47; 52 ± 10 years | Serum | ||
Goodarzi G | 2021 | January 2019 to Jan 2020 | Asian | Iran | 54 | 55 | 6.7 ± 1.35 nmol/L | 4.81 ± 1.09 nmol/L | M 32, F 22; 61.83 ± 7.78 years; T2DM | M 36, F 19; 58.71 ± 7.93 years | Serum | ||
Gozel N | 2021 | – | Caucasian | Turkey | 30 | 30 | 49.52 ± 41.98 ng/mL | 25.16 ± 14.49 ng/mL | M 17, F 13; 54.63 ± 10.8 years; newly diagnosed T2DM; treated with metformin | M 16, F 14; 30.10 ± 8.8 years | Plasma | ||
You M | 2022 | June to October 2021 | Asian | China | 33 | 30 | 173 ± 40.7 ng/mL | 158.5 ± 10.25 ng/mL | M 18, F 15; 60.85 ± 13.91 years; T2DM; duration of DM: 8 (3–14) years | M 16, F 14; 60.63 ± 8.08 years | Serum | ||
Dai C | 2022 | February 2021 to January 2022 | Asian | China | 90 | 66 | 7.38 ± 1.08 ng/mL | 5.87 ± 0.71 ng/mL | M 48, F 42; 54.91 ± 8.24 years; T2DM, treated with liraglutide | M 35, F 31; 52.15 ± 7.97 years | Serum | ||
Atli H | 2022 | May to August 2021 | Caucasian | Turkey | 21 | 21 | 28.22 ± 15.41 ng/mL | 25.49 ± 12.37 ng/mL | M 9, F 12; 56.05 ± 10.54 years; T2DM | M 15, F 6; 42.70 ± 7.55 years | Serum | ||
Timurkaan M | 2022 | – | Caucasian | Turkey | 60 | 60 | 47.7 ± 26.5 ng/mL | 35.7 ± 12.7 ng/mL | M 30, F 30; 50.3 ± 5.76 years; newly diagnosed T2DM | M 29, F 31; 47.6 ± 7.64 years | Plasma | ||
Boz IB | 2023 | October 2019 to November 2020 | Caucasian | Turkey | 30 | 33 | 42.8 ± 7.63 ng/mL | 20.5 ± 8.0 ng/mL | All females; 33.6 ± 5.6 years; GDM; gestational age: 27.1 ± 3.1 weeks | All females; 27.6 ± 4.6 years; gestational age: 25.6 ± 6.2 weeks | Serum | ||
Nedeva IS | 2023 | February 2020 to August 2021 | Caucasian | Bulgaria | 38 | 42 | 1.09 ± 0.51 ng/mL | 0.71 ± 0.28 ng/mL | 54.32 ± 10.97 years; newly diagnosed DM | 47.71 ± 12.91 years | Serum | ||